Lemonade Valuation
Is LMND * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of LMND * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate LMND *'s fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate LMND *'s fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for LMND *?
Other financial metrics that can be useful for relative valuation.
| What is LMND *'s n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | US$1.63b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.1x |
| Enterprise Value/EBITDA | -7.7x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does LMND *'s PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.9x | ||
Q * Quálitas Controladora. de | 1.2x | 10.1% | Mex$66.9b |
GNP * Grupo Nacional Provincial | 0.3x | n/a | Mex$31.3b |
ANSGR Anadolu Anonim Türk Sigorta Sirketi | 1.4x | n/a | ₺56.3b |
TSU Trisura Group | 0.7x | 11.8% | CA$2.0b |
LMND * Lemonade | 3.5x | 20.8% | Mex$1.6b |
Price-To-Sales vs Peers: LMND * is expensive based on its Price-To-Sales Ratio (3.5x) compared to the peer average (0.9x).
Price to Earnings Ratio vs Industry
How does LMND *'s PE Ratio compare vs other companies in the South American Insurance Industry?
Price-To-Sales vs Industry: LMND * is expensive based on its Price-To-Sales Ratio (3.5x) compared to the South American Insurance industry average (0.6x).
Price to Sales Ratio vs Fair Ratio
What is LMND *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 3.5x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate LMND *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | Mex$406.72 | Mex$336.69 -17.2% | 46.7% | Mex$708.81 | Mex$194.92 | n/a | 7 |
| Jul ’25 | Mex$300.99 | Mex$325.97 +8.3% | 45.3% | Mex$676.08 | Mex$185.92 | n/a | 7 |
| Jun ’25 | Mex$280.00 | Mex$325.97 +16.4% | 45.3% | Mex$676.08 | Mex$185.92 | n/a | 7 |
| May ’25 | Mex$300.00 | Mex$318.48 +6.2% | 48.3% | Mex$680.71 | Mex$170.18 | n/a | 7 |
| Apr ’25 | Mex$270.00 | Mex$312.61 +15.8% | 49.8% | Mex$678.54 | Mex$169.64 | n/a | 7 |
| Mar ’25 | Mex$288.00 | Mex$310.21 +7.7% | 50.8% | Mex$683.93 | Mex$170.98 | n/a | 7 |
| Feb ’25 | Mex$276.00 | Mex$310.17 +12.4% | 51.6% | Mex$689.27 | Mex$172.32 | n/a | 7 |
| Jan ’25 | Mex$299.00 | Mex$309.86 +3.6% | 57.2% | Mex$695.02 | Mex$173.76 | n/a | 6 |
| Dec ’24 | Mex$307.11 | Mex$304.63 -0.8% | 53.4% | Mex$687.88 | Mex$171.97 | n/a | 7 |
| Nov ’24 | Mex$197.00 | Mex$336.73 +70.9% | 49.2% | Mex$713.60 | Mex$160.56 | n/a | 8 |
| Oct ’24 | Mex$203.00 | Mex$325.75 +60.5% | 47.1% | Mex$702.21 | Mex$158.00 | n/a | 9 |
| Sep ’24 | Mex$241.00 | Mex$314.69 +30.6% | 48.1% | Mex$682.46 | Mex$136.49 | n/a | 9 |
| Aug ’24 | Mex$381.87 | Mex$312.44 -18.2% | 47.3% | Mex$669.52 | Mex$133.90 | n/a | 9 |
| Jul ’24 | Mex$290.00 | Mex$320.30 +10.4% | 48.1% | Mex$688.40 | Mex$137.68 | Mex$300.99 | 9 |
| Jun ’24 | Mex$323.00 | Mex$339.40 +5.1% | 48.7% | Mex$707.54 | Mex$141.51 | Mex$280.00 | 8 |
| May ’24 | Mex$190.00 | Mex$342.13 +80.1% | 46.1% | Mex$726.65 | Mex$181.66 | Mex$300.00 | 9 |
| Apr ’24 | Mex$272.00 | Mex$349.15 +28.4% | 45.0% | Mex$735.04 | Mex$183.76 | Mex$270.00 | 9 |
| Mar ’24 | Mex$274.00 | Mex$349.15 +27.4% | 45.0% | Mex$735.04 | Mex$183.76 | Mex$288.00 | 9 |
| Feb ’24 | Mex$304.25 | Mex$380.76 +25.1% | 46.0% | Mex$759.42 | Mex$189.86 | Mex$276.00 | 9 |
| Jan ’24 | Mex$266.01 | Mex$436.80 +64.2% | 37.2% | Mex$785.25 | Mex$274.84 | Mex$299.00 | 8 |
| Dec ’23 | Mex$366.00 | Mex$444.45 +21.4% | 35.0% | Mex$776.71 | Mex$271.85 | Mex$307.11 | 9 |
| Nov ’23 | Mex$479.50 | Mex$512.13 +6.8% | 33.1% | Mex$799.42 | Mex$279.80 | Mex$197.00 | 8 |
| Oct ’23 | Mex$440.00 | Mex$506.33 +15.1% | 34.0% | Mex$796.19 | Mex$278.67 | Mex$203.00 | 8 |
| Sep ’23 | Mex$440.51 | Mex$506.33 +14.9% | 34.0% | Mex$796.19 | Mex$278.67 | Mex$241.00 | 8 |
| Aug ’23 | Mex$415.00 | Mex$474.07 +14.2% | 36.7% | Mex$826.71 | Mex$289.35 | Mex$381.87 | 8 |
| Jul ’23 | Mex$380.00 | Mex$582.18 +53.2% | 42.8% | Mex$1,121.79 | Mex$310.50 | Mex$290.00 | 8 |
Analyst Forecast: Target price is lower than the current share price.